Business Wire

Functional Neuromodulation Initiates North American Study of Deep Brain Stimulation for Alzheimer’s Disease | Business Wire

TORONTO--(BUSINESS WIRE)--Functional Neuromodulation Ltd has initiated the ADvance Study in the U.S. and Canada to assess deep brain stimulation (DBS) in patients with mild Alzheimer’s disease.
Business Wire

Personalized Neuromodulation Treatment Significantly Slowed Alzheimer’s Progression in 12-month Phase 2 Study, Meeting Primary and Key Secondary Endpoints

Data presented at CTAD showed strong separation from placebo and statistical significance in mild-to-moderate patients on key global, cognitive, and behavioral measures including CDR-SB, ADAS- Cog 11 ...
Medscape

Personalized Noninvasive Neuromodulation Slows AD Progression

New research supports the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) for Alzheimer’s disease (AD). In a 52-week phase 2 trial, personalized rTMS applied over the ...

The Brain: From Black Box To Engineering Problem

As we enter 2026, there are two distinct technologies used by clinicians to interact with the brain: Brain-Computer ...
MarketWatch

Neuromodulation Market size is set to grow by USD 6.21 billion from 2024-2028, Growing geriatric population to boost the market growth, Technavio

NEW YORK, June 20, 2024 /PRNewswire/ -- The global neuromodulation market size is estimated to grow by USD 6.21 billion from 2024-2028, according to Technavio. The market is estimated to grow at a ...

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

Total national coverage footprint for PENFS increases to roughly 100 million covered livesCARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: ...